RSS

Xtandi

Astellas Pharma and Pfizer have announced an amendment to the clinical research protocol for the Phase III PROSPER trial evaluating XTANDI (enzalutamide) in patients with non-metastatic (M0) castration-resistant prostate cancer (CRPC) more

News

Thousands more cancer patients in England will be offered vital treatments in a £160 million boost to the Cancer Drugs Fund. more